Currently viewing the tag: "BioPorto"
NGAL – For the benefit of our esteemed readers from overseas- here is a transcript of todays article on BioPorto and Phadia in medwatch.dk
http://medwatch.dk/secure/Medicinal___Biotek/article4723291.ece
The relief and joy was measurable in the voice of Bioporto’s CEO (Thea Olesen) when MedWatch caught her on the phone, shortly after the danish Sea & Maritime Court […]
This week will see the verdict on the NGAL patent held by Phadia.
“Phadia – wasn’t that case solved years ago ?? “- you might ask… Well – lets just say that while the Legal system in Denmark might be just it is not exactly swift. The case – supposedly simple – has now dragged […]
Today BioPorto released its Q1 figures. Nothing much was expected, and nothing much was indeed the outcome. I will, as always, start with focusing on the area(s) that are disappointing. But don’t despair yet – hopefully I’ll end on a lighter note
If we look at the turnover – it was perhaps in accordance with […]
The Reasons for the decision by the EPO, regarding the revokation of the NGAL cutoff-patent are now available at the EPO website, in a document titled: “The Grounds for the decision”
In short – the OD does not find that the invention fulfills article 83 and article 100 (summary on page 11) – […]
The NGAL- test has hiherto primarily been connected with measurement of AKI. This will probably remain the most important area of use, but other areas – such as a marker for anemia are emerging
In a recent study a group of American doctors they investigated the relationship between NGAL-levels and anemia. The results are […]
Stengaard 9:41 PM after looking rather carefully at Abbotts “statement” to EPO – I have to conclude – there is nothing new… its more or less the same arguments that was presented the last time they lost… Mr. FillandKill 10:01 PM https://register.epo.org/espacenet/appli… https://register.epo.org/espacenet/advan… Mr. FillandKill 10:05 PM The first link is […]
Summer of 2011 brought – amongst record rains and rare floods in Denmark, an solicitation notice from US-Army to bid in for development of a urine-test (and device) that would help make the right selection of patients at – or close to – the battlefield.
At first we (we being – BioPorto Investors) thought […]
On the 28’th of December 2011, EPO issued the patent for Bioporto Diagnostics A/S, on the use of NGAL as a marker for the severity of a trauma…
Remember where you heard it first…. more will follow.
Is BioPorto trying to prevent usage of Alere’s Triage NGAL-test in its prime setting – the ER’s (Emergency Rooms) ?
As a consequence of the fact that EPO has declared they will issue the “Trauma patent” to Bioporto on the use of NGAL, an interesting question arises.
Will Bioporto use that patent to keep Alere/Biosite […]
Neue biomarker verbessern voraussage akuten.
in short : NGAL is better and cheaper than serum creatinine
In august 2010 the german contribution to the European Cardiology Congress was placed securely in the hands of Professor Dr. Günter Breithardt; His presentation carried the stunning title: New Biomarkers improve the prediction of acute renal damage significantly […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
